Search
Keros Therapeutics Inc
KROSAdd to Watchlist
10.500USD
-0.490-4.46%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
207.81MMarket Cap
LossP/E TTM
More Details of Keros Therapeutics Inc Company
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Keros Therapeutics Inc Info
Ticker SymbolKROS
Company nameKeros Therapeutics Inc
IPO dateApr 08, 2020
CEOSeehra (Jasbir)
Number of employees169
Security typeOrdinary Share
Fiscal year-endApr 08
Address1050 Waltham Street, Suite 302
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421
Phone16173146297
Websitehttps://www.kerostx.com/
Ticker SymbolKROS
IPO dateApr 08, 2020
CEOSeehra (Jasbir)
Company Executives of Keros Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
367.50K
+14.97%
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
9.78K
--
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
3.20K
+31.25%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
1.19K
-440.81%
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
--
-100.00%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Alpna Hansraj Seth, Ph.D.
Dr. Alpna Hansraj Seth, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lorena Lerner, Ph.D.
Dr. Lorena Lerner, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
367.50K
+14.97%
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
9.78K
--
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
3.20K
+31.25%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
1.19K
-440.81%
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, May 13
Updated: Wed, May 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
9.66%
Arrowstreet Capital, Limited Partnership
6.74%
State Street Investment Management (US)
5.44%
Vanguard Capital Management, LLC
4.20%
Madison Avenue Partners LP
4.16%
Other
69.79%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
9.66%
Arrowstreet Capital, Limited Partnership
6.74%
State Street Investment Management (US)
5.44%
Vanguard Capital Management, LLC
4.20%
Madison Avenue Partners LP
4.16%
Other
69.79%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
36.73%
Investment Advisor
31.57%
Hedge Fund
27.98%
Research Firm
4.75%
Private Equity
4.06%
Individual Investor
2.38%
Corporation
1.27%
Pension Fund
0.95%
Family Office
0.74%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
427
22.62M
114.30%
-32.59M
2025Q4
407
29.78M
97.74%
-30.16M
2025Q3
385
41.03M
124.11%
-17.81M
2025Q2
392
46.16M
114.02%
-7.54M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
1.91M
9.7%
-442.79K
-18.80%
Dec 31, 2025
Arrowstreet Capital, Limited Partnership
1.33M
6.77%
+1.08M
+415.75%
Dec 31, 2025
State Street Investment Management (US)
1.08M
5.46%
-226.99K
-17.42%
Dec 31, 2025
Madison Avenue Partners LP
823.71K
4.18%
--
--
Feb 17, 2026
OrbiMed Advisors, LLC
804.21K
4.08%
--
--
Dec 31, 2025
Qube Research & Technologies Ltd
783.92K
3.98%
+480.80K
+158.61%
Dec 31, 2025
Jacobs Levy Equity Management, Inc.
768.42K
3.9%
+161.34K
+26.58%
Dec 31, 2025
D. E. Shaw & Co., L.P.
755.47K
3.83%
-790.48K
-51.13%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
ALPS Medical Breakthroughs ETF
0.26%
State Street SPDR S&P Biotech ETF
0.21%
Federated Hermes MDT Small Cap Core ETF
0.12%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
ProShares Ultra Nasdaq Biotechnology
0.09%
WisdomTree US SmallCap Quality Growth Fund
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.76%
ALPS Medical Breakthroughs ETF
Proportion0.26%
State Street SPDR S&P Biotech ETF
Proportion0.21%
Federated Hermes MDT Small Cap Core ETF
Proportion0.12%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
